Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Karger Publishers 2023-05-01
Sarja:	Liver Cancer
Aiheet:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
Linkit:	https://beta.karger.com/Article/FullText/531182
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!